65,437 trials
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
Male Breast Cancer · Stage II Breast Cancer · Stage IIIA Breast Cancer
Primary: Congestive Heart Failure Rate — 2.9; 2.5 percentage of participants
Hyponatremia
Primary: Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores) — 0.20; 0.39 Z-score — p=0.08
Dysfunctional Central Venous Access Catheters
Primary: Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase — 72.0 percentage…
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 167.08; 167.41; 130.73; 137.87 mmHg
Hepatitis A · Hepatitis B
Primary: Number of Subjects Seropositive for Anti-hepatitis A Virus Antibodies (Anti-HAV) and Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies and With Anti-HBs Antibody…
Fever
Primary: Procalcitonin Level at ED Presentation — 18.47; 0.65 ng/dL — p=0.001
HIV Infections · Hepatitis C · Liver Disease
Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58
Bipolar Disorder
Primary: Proportion of Participants Not Experiencing Relapse to Any Mood Episode Through Week 52, Phase 3 — 1.00; 1.00; 0.95; 0.96 proportion of participants — p=0.014
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values. — 353; 358 Subjects
Asthma
Primary: The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period — 0; 0; 0; 0 participants
Hypertension; Hypertrophy, Left Ventricular
Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI) — -7.1; -9.1 g/m˄2
Pelvic Neoplasms
Primary: Number of Participants With Adverse Events — 0 partipants
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
Normal Healthy Subject Population
Primary: The Mean Percent Time Gastric pH > 4.0 on Day 1